My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 391

    1.

    Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.

    Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jetté L, Benquet C, Drucker DJ.

    Diabetes. 2003 Mar;52(3):751-9.PMID: 12606517 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.

    Baggio LL, Huang Q, Cao X, Drucker DJ.

    Gastroenterology. 2008 Apr;134(4):1137-47. Epub 2008 Jan 11.PMID: 18313669 [PubMed - indexed for MEDLINE]Related articles

    3.

    Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.

    Green BD, Gault VA, Irwin N, Mooney MH, Bailey CJ, Harriott P, Greer B, Flatt PR, O'Harte FP.

    Biol Chem. 2003 Dec;384(12):1543-51.PMID: 14719796 [PubMed - indexed for MEDLINE]Related articles

    4.

    Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.

    O'Harte FP, Mooney MH, Kelly CM, McKillop AM, Flatt PR.

    Regul Pept. 2001 Jan 12;96(3):95-104.PMID: 11111014 [PubMed - indexed for MEDLINE]Related articles

    5.

    N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.

    Green BD, Mooney MH, Gault VA, Irwin N, Bailey CJ, Harriott P, Greer B, O'Harte FP, Flatt PR.

    J Endocrinol. 2004 Mar;180(3):379-88.PMID: 15012592 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis.

    Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ.

    J Biol Chem. 2003 Jan 3;278(1):471-8. Epub 2002 Oct 29.PMID: 12409292 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.

    Holst JJ.

    Expert Opin Emerg Drugs. 2004 May;9(1):155-66. Review.PMID: 15155141 [PubMed - indexed for MEDLINE]Related articles

    8.

    A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

    Baggio LL, Huang Q, Brown TJ, Drucker DJ.

    Diabetes. 2004 Sep;53(9):2492-500.PMID: 15331566 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1.

    Burcelin R, Dolci W, Thorens B.

    Metabolism. 1999 Feb;48(2):252-8.PMID: 10024091 [PubMed - indexed for MEDLINE]Related articles

    10.

    Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.

    Baggio LL, Huang Q, Brown TJ, Drucker DJ.

    Gastroenterology. 2004 Aug;127(2):546-58.PMID: 15300587 [PubMed - indexed for MEDLINE]Related articles

    11.

    Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.

    Green BD, Gault VA, Mooney MH, Irwin N, Harriott P, Greer B, Bailey CJ, O'Harte FP, Flatt PR.

    Biol Chem. 2004 Feb;385(2):169-77.PMID: 15101559 [PubMed - indexed for MEDLINE]Related articles

    12.

    Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo.

    Xiao Q, Giguere J, Parisien M, Jeng W, St-Pierre SA, Brubaker PL, Wheeler MB.

    Biochemistry. 2001 Mar 6;40(9):2860-9.PMID: 11258897 [PubMed - indexed for MEDLINE]Related articles

    13.

    KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity.

    Kim KR, Rhee SD, Kim HY, Jung WH, Yang SD, Kim SS, Ahn JH, Cheon HG.

    Eur J Pharmacol. 2005 Jul 25;518(1):63-70.PMID: 16106524 [PubMed - indexed for MEDLINE]Related articles

    14.

    Identifying glucagon-like peptide-1 mimetics using a novel functional reporter gene high-throughput screening assay.

    Chen J, Bai G, Yang Y, Geng P, Cao Y, Zhu Y.

    Peptides. 2007 Apr;28(4):928-34. Epub 2006 Dec 27.PMID: 17267075 [PubMed - indexed for MEDLINE]Related articles

    15.

    Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.

    Green BD, Gault VA, Mooney MH, Irwin N, Bailey CJ, Harriott P, Greer B, Flatt PR, O'Harte FP.

    J Mol Endocrinol. 2003 Dec;31(3):529-40.PMID: 14664713 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.

    Drucker DJ.

    Curr Pharm Des. 2001 Sep;7(14):1399-412. Review.PMID: 11472275 [PubMed - indexed for MEDLINE]Related articles

    17.

    Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo.

    Baggio LL, Kim JG, Drucker DJ.

    Diabetes. 2004 Dec;53 Suppl 3:S205-14.PMID: 15561912 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.

    Holz GG, Chepurny OG.

    Curr Med Chem. 2003 Nov;10(22):2471-83. Review.PMID: 14529486 [PubMed - indexed for MEDLINE]Related articles

    19.

    Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling.

    Scrocchi LA, Marshall BA, Cook SM, Brubaker PL, Drucker DJ.

    Diabetes. 1998 Apr;47(4):632-9.PMID: 9568697 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action.

    Scrocchi LA, Hill ME, Saleh J, Perkins B, Drucker DJ.

    Diabetes. 2000 Sep;49(9):1552-60.PMID: 10969840 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity